RAMM Pharma Corp. (RAMM.CN)

CAD 0.01

(0.0%)

Market Cap (In CAD)

1.19 Million

Revenue (In CAD)

5.06 Million

Net Income (In CAD)

-7.72 Million

Avg. Volume

11.03 Thousand

Currency
CAD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.005-0.065
PE
-
EPS
-
Beta Value
-0.207
ISIN
CA75150G1046
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Jackie Peter Burnett
Employee Count
-
Website
https://www.rammpharma.com
Ipo Date
2019-11-08
Details
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.